Showing results (191-200 of 203) with videos related to

Sort By:
Pageof 21
Current Pharmaceutical Design|April 12, 2002
Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trialF Perrone, C Gallo, B Daniele, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2021
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD IK N Moore, A M Oza, N Colombo, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 2025
Predictive value of BRCA1/RAD51C methylation in HGSOC - An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trialH Blons, J Abdelli, S Landman, et al.
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|March 6, 2026
Radiomics-based ultrasOund Model for differentiating Uterine Sarcomas from leiomyomas (ROMUS): a retrospective pilot Multicenter Italian Trials in Ovarian Cancer (MITO) studyF Ciccarone, A Rizzi, A Biscione, et al.
ESMO Open|April 2, 2025
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world studyC Marchetti, A Fagotti, R Fruscio, et al.
Gynecologic Oncology|September 28, 2020
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trialMansoor R Mirza, B Benigno, A Dørum, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent diseaseM K Wilson, E Pujade-Lauraine, D Aoki, et al.
ESMO Open|November 19, 2025
PARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric surveyM Turinetto, C Marchetti, G Scandurra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2025
Dostarlimab and niraparib in primary advanced ovarian cancerA-C Hardy-Bessard, E Pujade-Lauraine, R G Moore, et al.
ESMO Open|January 25, 2023
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancerS Koppikar, A Oaknin, K Govind Babu, et al.
Pageof 21